



Docket No.: 37998-237338  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Heinz VON DER KAMMER et al.

Art Unit: 1614

Application No: 10/588,274

Examiner: Not Yet Assigned

Confirmation No: 5018

Filed: February 3, 2005

Atty. Docket No: 37998-237338

For: DIAGNOSTIC AND THERAPEUTIC USE OF  
THE KCNE4 GENE AND PROTEIN FOR  
ALZHEIMER'S DISEASE

Customer No:  
26694  
PATENT TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear on any Patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Documents BA-BE, CA and CD were cited in an International Search Report. Documents AA and CA-CD were cited in a European Search Report. Copies of the International Search Report and the European Search Report are attached.

Copies of documents BA-BE, CA and CD are not being provided since copies are furnished directly by WIPO under an exchange program between the PTO, the EPO and the JPO. Copies of documents CB and CC, cited in the European Search Report only, are submitted herewith.

If the copies were not furnished and a copy of a cited document is desired, please inform the undersigned and a copy of the missing document will be supplied.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portion of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0261, under Order No. 37998-237338. A fee transmittal is also enclosed.

Dated: 4/27/2007

Respectfully submitted,

By Kavita B. Lepping  
Kavita B. Lepping  
Registration No.: 54,262  
VENABLE LLP  
P.O. Box 34385  
Washington, DC 20043-9998  
(202) 344-4000  
(202) 344-8300 (Fax)  
Attorney/Agent For Applicant

#848415